Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1647
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18361179 | ANTI-GARP-TGF-BETA1/PD-1 COMBINATION THERAPY | Non-Final OA | AbbVie Deutschland GmbH & Co. KG |
| 18188168 | COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY | Final Rejection | Genentech, Inc. |
| 18294767 | METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18123112 | CAR CELLS TARGETING AN INSERTED LIGAND | Final Rejection | Massachusetts Institute of Technology |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | Non-Final OA | Gilead Sciences, Inc. |
| 18299877 | PHARMACEUTICAL COMPOSITIONS OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND METHODS OF USE | Final Rejection | Hoffmann-La Roche Inc. |
| 18703972 | METHOD FOR DETECTING KIDNEY DYSFUNCTION DIAGNOSTIC MARKER, METHOD FOR DETERMINING RENAL PROGNOSIS, DETECTION KIT FOR KIDNEY DYSFUNCTION DIAGNOSTIC MARKER, AND KIDNEY DYSFUNCTION DIAGNOSTIC MARKER | Non-Final OA | Japanese Foundation for Cancer Research |
| 18561347 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SOLID TUMORS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18684711 | ANTI-HLA-G ANTIBODIES | Non-Final OA | UCB BIOPHARMA SRL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy